In a landmark decision that could reshape the treatment landscape for obesity-related heart disease in England, over one million additional patients have become eligible to receive Wegovy on the NHS from 1 April 2026. The move follows new guidance from the National Institute for Health and Care Excellence (NICE), and represents a major expansion of access to one of the most talked-about weight-loss drugs of the decade.
What Is Wegovy and How Does It Work?
Wegovy is the brand name for semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. Originally developed to treat Type 2 diabetes, semaglutide was found in clinical trials to produce substantial weight loss — often in the range of 10–15% of body weight — when used alongside diet and exercise. Administered via a weekly self-injection, it works by mimicking a hormone that regulates appetite, helping patients feel fuller for longer and reducing overall calorie intake.
The drug made headlines when it became available through NHS specialist weight management services, but access was limited due to strict eligibility criteria and capacity constraints within those specialist services. That is now changing.
The April 2026 NICE Guidance: Who Is Now Eligible?
Under guidance published on 1 April 2026, Wegovy can now be prescribed on the NHS to patients who meet the following criteria:
- A BMI of 27 or greater
- A history of cardiovascular disease, specifically those who have previously experienced a heart attack, stroke, or serious circulation problems in the legs
This represents a fundamentally different eligibility route from the existing weight-management pathway. Previously, patients needed to meet higher BMI thresholds and be referred to specialist services. Now, GPs will be able to prescribe Wegovy directly to patients who fit the cardiovascular risk profile — potentially transforming how quickly people can access treatment.
The British Heart Foundation (BHF) estimates that this guidance opens up access to around 1.2 million additional patients in England alone — a dramatic increase that will place significant demands on NHS prescription budgets and pharmaceutical supply chains.
What Does This Mean for Patients?
For the millions of people in the UK living with both obesity and cardiovascular conditions, this is welcome news. Research published in recent years has demonstrated that semaglutide doesn’t just aid weight loss — it also significantly reduces the risk of further cardiovascular events in high-risk patients. The NICE guidance reflects this growing body of clinical evidence, recognising Wegovy as both a weight management tool and a cardiovascular risk reduction treatment.
Patients who believe they may now be eligible are advised to speak to their GP, who will be able to assess whether Wegovy is appropriate based on their full medical history, current medications, and overall health profile.
Existing Weight-Loss Eligibility Criteria Remain Unchanged
For those seeking Wegovy purely for weight management purposes — without the cardiovascular disease background — the existing criteria remain in place. These patients must:
- Have at least one weight-related health condition such as hypertension, Type 2 diabetes, or sleep apnoea
- Have a BMI of at least 35 (or 30–34.9 with additional risk factors)
- Be referred to a specialist NHS weight management service
Access through this route remains constrained by the limited number of specialist services across the country, and waiting times can be considerable depending on local NHS provision.
Is a Wegovy Pill on the Way?
One of the most significant developments on the horizon is the potential approval of an oral version of Wegovy. Novo Nordisk has been developing a pill formulation of semaglutide, and a UK regulatory decision is expected in late 2026. If approved, NHS access would likely follow in 2027, potentially opening up treatment to a wider cohort of patients who are reluctant to self-inject or for whom injections are impractical.
Cost and Sustainability Concerns
Wegovy is not cheap. The annual cost of treatment can run into the thousands of pounds per patient, raising legitimate questions about NHS sustainability if uptake scales as expected. Health economists and NHS strategists are closely monitoring the rollout, and the government has negotiated a confidential commercial arrangement with Novo Nordisk to manage costs.
Supporters of expanded access argue that the long-term savings — in terms of reduced hospitalisations, fewer heart attacks and strokes, lower demand for surgical interventions, and improved productivity — more than justify the upfront investment. Critics caution that the drug is not a silver bullet and that lifestyle change, public health infrastructure, and systemic food policy reform remain essential components of any serious obesity strategy.
The Bigger Picture
The expansion of NHS Wegovy access sits within a broader national conversation about obesity, healthcare spending, and personal responsibility. For many patients, particularly those who have struggled with weight for years without success through conventional methods, this drug represents a genuine lifeline. The April 2026 changes are a significant step — and with the oral pill potentially on the way, access may expand even further in the months and years ahead.